ClinicalTrials.gg
RecruitingNCT00595491Updated Nov 6, 2026

Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation

A Phase 1 interventional study of Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage in Asthma, sponsored by Benjamin Medoff. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Benjamin Medoff · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2008; still recruiting 18 years 10 months later.
Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
313
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.

Planned enrollment
377th of 1,354
313 · median 100
Started
2008
with 91 others
Phase 1
128 of 1,696
11 open now
Primary completion
2029-12
later than 171 of 184 live
Registered
324th of 1,696
by date

Among the 1,696 studies in Asthma with a site in United States, this one is the 377th largest by planned enrollment of the 1,354 interventional ones that give a count, is one of 92 that started in 2008, is one of 128 in phase 1, reaches primary completion later than 171 of the 184 other live ones, and was the 324th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,696 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation. This work is designed to identify airway factors that are responsible for recruiting cells and associate their airway presence with atopy and asthma.

Read the detailed description

The production of chemotactic cytokines or chemokines by the airways is one of the mechanisms thought to be responsible for the recruitment of inflammatory cells to the airways (Makay 2001). While the chemokine receptor-ligand systems responsible for immune cell homing to the mucosal surface of the gastrointestinal tract have been clarified, those responsible for allergic airway inflammation remain unknown. This work is designed to identify airway factors that are responsible for recruiting cells and associate their airway presence with atopy and asthma.

03

Conditions studied

  • Asthma

Keywords

  • Asthma
  • Inflammation
  • Allergic
  • Airway
  • Challenge
  • Chemokines
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

A. Subjects with Allergic Asthma (AA subjects)

Inclusion Criteria:

  1. All subjects will have a baseline determined at the characterization visit that is no less than 75 % of the predicted value.
  2. All subjects will have a clinical history of allergic symptoms to cat or dust mite allergen and demonstrated skin reactivity (a positive allergen prick test).
  3. Life-long absence of cigarette smoking (defined as a lifetime total of less than 5 pack-years); none in 5 years).
  4. Willing and able to give .
  5. Expressed the desire to participate in an interview with the principal investigator.
  6. Age between 18 and 50 years.

Exclusion Criteria:

  1. Women of who are documented to be pregnant (based on Urine beta-HCG testing), are sexually active and not using , are seeking to become pregnant, or who are nursing.
  2. The presence of spontaneous asthmatic episode or clinical evidence of upper respiratory tract infection within the previous 6 weeks.
  3. Participation in research study involving a drug or biologic during the 30 days prior to the study.
  4. Intolerance to albuterol, atropine, lidocaine, fentanyl, or midazolam.
  5. Antihistamines within 7 days of the screening visit.
  6. Presence of diabetes mellitus, congestive heart failure, ventricular arrhythmias, history of a cerebrovascular accident, renal failure, history of anaphylaxis, or cirrhosis.
  7. Use of systemic , increased use of inhaled steroids, beta blockers and MAO inhibitors or a visit for an asthma exacerbation within 1 month of the screening visit.
  8. Antibiotic use for respiratory disease within 1 month of the characterization visit or a respiratory tract infection within 6 weeks of the bronchoscopy visits.
  9. A history of asthma-related respiratory failure requiring intubation.
  10. Quantitative skin-prick test positive reaction down to an allergen concentration of 0.056 BAU or AU/ml .
  11. Taking beta-adrenergic blocking agents or monoamine oxidase inhibitors.
  12. Subjects with a high possibility of poor compliance with the study.
  13. No history of cigarette smoking within the past 5 years or > 10 pack years total.
  14. Having second-hand cigarette smoke exposure or indoor furry pets except in the case of dog, if the subject is not allergic to the dog and the subject has a negative skin test to dog (It is also preferred but not required that dust mite allergic subjects have dust mite-proof encasings on their mattress and pillows.)
  15. Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection.
  16. Use of Xolair (omalizumab - anti-IgE monoclonal antibody) for 6 months.
  17. Immunotherapy with cat or dust mite extract now or in the past.
  18. Non-English speakers.
  19. History of coagulopathy, thrombocytopenia, pulmonary hypertension, and/or use of anti-coagulants/anti- drugs.

B. Healthy Normal Control Subjects (NC subjects)

Normal control subjects will be individuals who are in good overall health, age and sex matched to the asthmatic group, age 18 - 50 and nonallergic, i.e. entirely negative on the panel of prick skin tests listed in section V (Study Procedures), with no history of allergic rhinitis or asthma, no history of allergic symptoms caused by cats or dust mite allergen exposure, life-long nonsmokers of cigarettes (defined as a lifetime total of less than 5 pack-years and none in 5 years), normal spirometry (i.e. FEV1 and FVC of at least 90% of predicted) and with a methacholine PC20 of > 16 mg/ml.

Exclusion Criteria:

  1. A history of allergy, asthma, nasal or sinus disease.
  2. Exclusion criteria #1, 3-8 and 10-19 from (A.) above.

C. Allergic Nonasthmatic Subjects (ANA subjects)

Inclusion Criteria:

  1. ANA subjects will have a history of either (a) allergic rhinitis (with one or more of the following symptoms: nasal congestion, sneezing, runny nose, postnasal drainage), (b) allergic conjunctivitis (ocular itching, tearing and/or swelling) or (c) contact allergy associated with cat dander or dust mite and a positive allergy test to the same allergen.
  2. All subjects will have a baseline FEV1 and FVC determined at the characterization visit that is no less than 90 % of the predicted value.
  3. All subjects will have a positive allergy skin prick test to cat dander or dust mite allergen.
  4. All subjects will be in good general health.
  5. Life-long absence of cigarette smoking (defined as a lifetime total of less than 5 pack-years and none in 5 years).
  6. Willing and able to give informed consent.
  7. Expressed the desire to participate in an interview with the principal investigator.
  8. Age between 18 and 50 years.

Exclusion Criteria:

  1. A history of asthma.
  2. Exclusion criteria #1, 3-8 and 10-19 from (A.) above.
  3. A methacholine PC20 \< 16 mg/ml.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
313 participants (estimated)

Study arms

  • Experimental
    allergic asthmatic, allergic nonasthmatic, healthy

    Adults who are allergic asthmatics, allergic nonasthmatics, or healthy controls will receive segmental allergen challenge to the lung

    Biological: Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage

Interventions

  • BiologicalBronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage

    Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.

    Also known as: One of 3 Standardized allergen extracts will be used:, Standardized Cat Hair Extract, Standardized mite extract-Dermatophagoides farinae, Standardized mite extract-Dermatophagoides pteronyssinus, Phenolized saline diluent will also be used in this study., All will be purchased from Greer Laboratories Lenoir,NC.

06

What researchers measure

Primary outcomes

  1. airway inflammation

    Time frame: 1,6, or 24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Summary and recommendations of a workshop on the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in asthmatics. Am Rev Respir Dis. 1985 Jul;132(1):180-2. doi: 10.1164/arrd.1985.132.1.180. PubMed 4014864 ↗
  • Busse WW, Lemanske RF Jr. Asthma. N Engl J Med. 2001 Feb 1;344(5):350-62. doi: 10.1056/NEJM200102013440507. No abstract available. PubMed 11172168 ↗
  • Djukanovic R, Wilson JW, Lai CK, Holgate ST, Howarth PH. The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma. Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):772-7. doi: 10.1164/ajrccm/143.4_Pt_1.772. PubMed 2008989 ↗
  • Jarjour NN, Peters SP, Djukanovic R, Calhoun WJ. Investigative use of bronchoscopy in asthma. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):692-7. doi: 10.1164/ajrccm.157.3.9705020. PubMed 9517577 ↗
  • Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med. 2001 Jan 11;344(2):109-13. doi: 10.1056/NEJM200101113440206. No abstract available. PubMed 11150362 ↗
  • Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol. 2001 Feb;2(2):95-101. doi: 10.1038/84298. PubMed 11175800 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2008 (actual). Primary completion is estimated for Dec 2029, 263 months after the start.

Of 200 phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 263 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Dec 2028 → Dec 2029 and completion Jan 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2008
First posted
Jan 16, 2008
StartActual
Jan 2008
Primary completionEst.
Dec 31, 2029was Dec 2028
CompletionEst.
Jan 31, 2030was Jan 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2028→Dec 31, 2029
Nov 6, 2026
Study completion
Jan 31, 2029→Jan 31, 2030
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Dec 31, 2028→Dec 31, 2029
    Study completion Jan 31, 2029→Jan 31, 2030
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00595491
Lead sponsor
Benjamin Medoff
Responsible party
Benjamin Medoff (Chief, Pulmonary and Critical Care Unit, Massachusetts General Hospital) — Sponsor-investigator
First posted
Jan 16, 2008
Start date
Jan 2008
Primary completion
Dec 31, 2029 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Daniel L Hamilos, MD
Contact
dhamilos@partners.org
617-726-5090
Benjamin D Medoff, MD
Contact
bmedoff@partners.org
617-726-6695
Benjamin D Medoff, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion